Name

ara-C/MTX

Alternate names

None

Primary Site

None

Histology

None

Radiation

None

Remarks

None

Drugs for ara-C/MTX

Name

Alternate Names

Amethopterin
Antifolan
CL-14377
Folex
Methotrexate Sodium
Mexate
Mexate AQ
Rheumatrex
WR-19039

Abbreviations

MTX

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

740
000740

Primary Site

Acute lymphoblastic leukemia (ALL)
Bladder cancer
Breast
Gestational trophoblastic cancer
head & neck cancer
lymphoma
Meningeal leukemia
Non-Hodgkin lymphoma
Osteogenic sarcoma
Primary CNS lymphoma

Histology

None

Remarks

FDA approved uses on ALL, breast cancer, choriocarcinoma, head and neck cancer, lymphoma, and osteosarcoma.

Coding

This drug should be coded

Name

Alternate Names

AC-1075
Alexan
Ara-cytidine
Arabinocytidine
Arabinosylcytosine
Beta-Arabinosylcytosine
Cytarabin
Cytarabine
Cytarabinoside
Cytosar
Cytosar-U
Cytosine Arabinoside
Cytosine arabinoside hydrochloride
Spongocytidine HCL
Tarabine
Tarabine PFS
U-19920
U-19920A
WR-28453

Abbreviations

ara-C
CA
HDA
HDARA-C

Category

Chemotherapy

Subcategory

Antimetabolite

NSC Number

063878
63878

Primary Site

ALL
AML
CML
head and neck
Hodgkin's disease
leukemia
Meningeal leukemia
NHL

Histology

None

Remarks

Antineoplastic agent; antimetabolite. FDA approved uses on Hodgkin's disease, leukemia; under investigation for Rx of Progressive Multifocal Leukoencephalopathy (PML)

Coding

This drug should be coded

Name

Alternate Names

G-CSF
GCSF
Neupogen
Zarxio
r-G-CSF
r-met Hu G-CSF
rhG-CSF

Abbreviations

None

Category

Ancillary Agent

Subcategory

None

NSC Number

614371
614629

Primary Site

None

Histology

None

Remarks

A granulocyte colony-stimulating factor (G-CSF). Adjunct of Ganciclovir therapy; treatment of neutropenia

March 2015: Zarxio is the first biosimilar product approved in the United States. A biosimilar product is a biological product that is based on a showing that it is highly similar to an already-approved biological product, known as a reference product. There are no differences in terms of safety and effectiveness from the reference product (neupogen)

Coding

This drug should NOT be coded
Glossary